8:30 am Registration & Morning Refreshments
9:15 am Chair’s Opening Remarks
Optimizing Pairing of Target, Antibody & Linker-Payload Technologies
9:30 am Showcasing Affilins® – a Novel, Best-in-Class Targeting Platform
Synopsis
- Breaking paradigms in tumor accumulation
- Unprecedented modularity for fast innovation cycles multi-specifics without limits
10:00 am Uncovering Why Topoisomerase-1 Payloads Have Had Great Success in ADC Development
Synopsis
- Discussing benefits of utilising Topo-1 payloads as ADC warhead
- Understanding why Topo-1 payloads have been successful in ADC development
- Linking target selection with payload selection: what has topo-1 allowed us to do in terms of targets?
10:30 am Morning Refreshments
11:30 am Implications of Patient Selection When Utilizing Novel ADC Targets
Synopsis
- Identifying what is relevant in pre-treated patients
- Discussing biomarkers to identify patients who will respond well to an ADC target
- Targeting certain oncology patients in a novel method
Advancing Your Understanding of Target Biology to Aid in Target Selection
12:00 pm Roundtable Discussion: Delving Into Fc Function for Target Specificity: Is It Always Necessary?
Synopsis
- Determining if Fc function is necessary for your Fc target specificity
- Exploring better choices when wanting to avoid Fc Function
- Understanding cytotoxic effects linked to Fc function
12:30 pm Networking Lunch
Overcoming Challenges in Clinical Applicability & Pipeline Development in the ADC Sphere
1:30 pm Pre-Clinical Discovery & Evaluation of BoltbodyTM Immune-Stimulating Antibody Conjugates (ISACs) for Solid Tumors
Synopsis
- Delving into the story of pre-clinical discovery of ISACs
- Outlining how ISACs are beneficial in the pursuit of treatments for solid tumours
- Evaluating the Boltbody ISAC